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Three 8-aminoquinolines from the Walter Reed Army Institute for Research (WRAIR), WR6026,
WR238605, and WR242511, strongly inhibited Pneumocystis carinii growth in vitro at 1 ,Lg/nil his activity
was similar to that of primaquine. In rat therapy models, the WRAIR compounds affected Pneumocystis
pneumonia at doses as low as 0.25 mg/kg (WR242511) or 0.5 mg/kg (WR6026 and WR238605). At these doses,
primaquine alone was ineffective as therapy. In a rat prophylaxis model, all three WRAIR 8-aminoquinolines
were extremely effective at daily doses of 0.57 mg/kg, showing activity greater than that of primaquine at this
dosage and comparable to that of trimethoprim-sulfamethoxazole at 50/250 mg/kg.
In the United States, Pneumocystis carinii causes pneu-
monia in 60 to 80% of individuals infected with the human
immunodeficiency virus. Traditional therapeutic and pro-
phylactic regimens, including trimethroprim-sulfamethox-
azole and pentamidine, can cause severe adverse reactions
in this group of patients. The search for alternative drugs
that are effective against P. carinii led to the discovery that
the drug combination clindamycin-primaquine is effective
both in vitro and in animal models for both therapy and
prophylaxis (11). The combination proved effective in ani-
mals, although neither drug was effective alone. The regimen
has been carried on to clinical therapy trials (6, 12, 13) and
appears to be very effective for the treatment of P. carinii
pneumonia. Results of clinical studies carried out by E.
Toma in Montreal, Quebec, Canada, in which clindamycin-
primaquine was compared with trimethoprim-sulfamethox-
azole have not yet been published. Studies of other 8-ami-
noquinolines related to primaquine were undertaken to find
agents with efhanced effectiveness, less toxicity than pri-
maquine, or both.
Many 8-aminoquinolines have been synthesized and
tested for activity against protozoal infectiws.jThe Walter
Reed Army Institoe for Research (WRAIRJ has actively
pursued the develboment of 8-aminoquinolines for antima-
larial and antileishmnailial activities (8). Three WRAIR com-
pounds were selected that were more potent antimalarial
agents than primaquine qnd for which pharmacologic and
toxicologic data were avaita'ble (3). Compound WR6026 has
entered phase II testing in humans for leishmaniasis, and
WR238605 is being considered for phase I and II testing in
humans as an antimalarial agent. In animals, WR242511 has
been more active against malaria than WR6026 or WR238605
has, but it has a greater potential for producing methemo-
globinemia. The advanced state of development of the drugs




The in vitro culture system for evaluating compounds for
anti-P. carinii activity has been described previously (2).
Briefly, 24-well tissue culture plates (Coming) containing
confluent monolayers of WI-38 human embryonic lung fibro-
blasts in minimum essential medium (Sigma) with 10% fetal
bovine serum (Whittaker M.A. Bioproducts) were inocu-
lated with approximately 7 x 105 P. cariniii trophozoites per
well. The drugs to be tested were added to the wells so that
for each drug concentration there were four wells to be
examined at each of five time points. Wells with no drugs
and wells with trimethoprim-sulfamethoxazole at 50/250
jxg/ml were included as controls. Plates were incubated at
35°C in an atmosphere of 5% 02 and 10% C02, with the
balance being N2. On days 1, 3, 5, 7, and 10, 10-,u samples
were removed from the wells, placed on glass slides in 1-cm2
areas, stained with Giemsa, and examined microscopically
at x 1,000. P. carinii trophozoites and cysts as well as tissue
culture cells were counted in 10 randomly selected fields of
unknown slides by two individuals. For each time point,
there were eight evaluations (four wells x two examiners)
from which means and standard errors were calculated and
plotted to provide growth curves.
Inocula for cultures and for animals were prepared from
infected rat lungs. Samples of lungs known to be infected, as
determined by examination of Giemsa-stained impression
smears, were ground in a Ten-Broeck homogenizer in min-
imum essential medium, and centrifuged slowly (250 x g) to
settle the lung pieces, and the supernatant was decanted. A
10-,ul sample of supernatant was stained with Giemsa as well
as with viability stain (5) and examined microscopically. The
number of trophozoites per milliliter was determined, and
the inoculum was adjusted as necessary.
Animal models. Animal models were used both at Indiana
University (IU) and the University of North Carolina
(UNC). Since the models differed in several aspects, each
model is described below.
(i) Animal models at IU. For the transtracheally inoculated
rat model for treatment or prophylaxis (1), virus-free female
rats (weight, 120 to 140 g; Harlan-Sprague-Dawley, barrier
202, in Indianapolis, Ind.) which were also free of P. carinii
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FIG. 1. Inhibition of P. carinii by the three WRAIR compounds. Data are from experiments 48 (A), 49 (B), 50 (C), and 89 (D).
were used. The animals received standard chow containing
23% protein and also received tetracycline (0.5 mg/ml) in the
drinking water. Before being inoculated transtracheally, rats
were immunosuppressed for 4 days either with dexametha-
sone at 1.2 ,ug/ml in drinking water or with cortisone acetate
injected subcutaneously at 250 mg/kg twice per week, as
specified for each study. The choice of immunosuppressive
agent was determined by the drugs being tested in the study.
Earlier studies showed that animals would not drink water
containing dexamethasone along with clindamycin-pri-
maquine (unpublished data from IU). For transtracheal
inoculation, after 4 to 7 days of immunosuppression, rats
were anesthetized intramuscularly with 0.2 ml of a "cock-
tail" containing ketamine hydrochloride (80.0 mg/ml), atro-
pine (0.38 mg/ml), and acepromazine (1.76 mg/ml); and an
incision of approximately 1 cm was made over the trachea,
which was then exposed by blunt dissection. The inoculum
of 106 trophozoites in 0.2 ml was injected followed by
injection of 0.4 ml of air; the wound was closed with a single
clip. Animals were continued on immunosuppressive agents.
A Control
- WR238605 lOug/ml






- WR24251 1 lOug/ml









































8-AMINOQUINOLINES FOR PNEUMOCYSTIS PNEUMONIA
TABLE 1. Treatment at IU of P. carinii pneumonia in rats with 8-aminoquinolines from WRAIR
Giemsa
Drug Dose stain No. infected/ Silver stain No. infected/(mg/kg/day) infectivity total no. infectivity score, total no.
scorea
WR6026 2 2.2 ± 0.4b 10/10 1.8 ± 0.3 10/10
WR238605 2 1.8 ± 0.3c 10/10 1.8 ± 0.3 8/9
WR242511 2 0.2 ± 0.1c 4/10 0.5 ± 0.4 10/10
Untreated control 4.2 ± 0.1 7/7 3.7 ± 0.2 7/7
Trimethoprim-sulfamethoxazole 50/250 0.5 ± 0.4c 4/6 0.9 ± 0.7 5/6
a Results are expressed as means ± standard errors. The scores are described in the text.
b P < 0.01 compared with untreated controls.
c P < 0.001 compared with untreated controls.
For the therapy model, treatment was begun 4 weeks later
and was continued for 2 to 3 weeks. For the prophylaxis
model, drug administration was begun after transtracheal
inoculation and was continued for 6 to 7 weeks. Animals
were monitored daily and were weighed weekly. Drug doses
were given by gavage or were added to drinking water and
assessed by monitoring water consumption. At the time of
sacrifice, animals were anesthetized with ketamine cocktail
(0.2 ml intramuscularly) and were exsanguinated by cardiac
puncture. Lungs were removed and used to prepare impres-
sion smears and sections, which were stained with Giemsa
and rapid methenamine silver nitrate stains. Stained prepa-
rations were examined as unknowns by three individuals,
and scores of infection were determined by the following
scheme, which is approximately logarithmic and is based on
the numbers of organisms per x1,000 field: >100, 5; 11 to
100, 4; 1 to 10, 3; 2 to 9 per 10 fields, 2; <1 in 10 fields, 1; 0
in 50 fields, 0. Standard errors of mean scores were calcu-
lated for each group of animals. P values were calculated and
are given when appropriate. Ten rats were given each drug
dose, and both untreated controls and positive controls
treated with trimethoprim-sulfamethoxazole (50/250 mg/kg)
were included.
(ii) Animal model at UNC. Male Sprague-Dawley rats
(weight, 150 to 200 g) not certified to be virus-free were
obtained from Hilltop Laboratories (Scottsdale, Pa.). Ani-
mals received a low-protein diet (8%), drinking water con-
taining tetracycline (0.5 mg/ml), and for immunosuppres-
sion, cortisone acetate at 250 mg/kg injected subcutaneously
twice weekly. The regimen was continued for 8 weeks, with
fluid intake being monitored- daily and animals weighed
weekly. After 6 weeks, animals were placed in eight groups
of 10 animals each. Test compounds were given in the
drinking water. At the end of 2 weeks of treatment with the
test compounds, all animals were sacrificed by exsan-
guination following anesthesia. The lungs were inflated in
situ with 10% Formalin and fixed for histologic examination.
The lung tissue was sectioned and stained with the Grocott
methenamine silver stain. Two scorers determined the ex-
tent of lung involvement as follows: <10 cysts per two fully
examined sections, 0.5; scattered cysts, <5% of lung in-
volved, 1; scattered cysts with limited focal involvement 10
to 25% of lung involved, 2; scattered cysts with numerous
intense areas of focal involvement and 26 to 50% of lung
involved, 3; cysts throughout the tissue with numerous very
intense focal areas and 75% of lung involved, 4.
In all studies described here, 8-aminoquinolines provided
by WRAIR to investigators at both IU and UNC were used.
RESULTS
In vitro cultures showed that all three compounds inhib-
ited P. carinii at 10 and 1 ,ug/ml; they were still somewhat
inhibitory at 0.1 ,ug/ml (Fig. 1). In one experiment, com-
pound 242511 appeared to be very effective at 0.1 jig/ml.
This level of activity was similar to that observed previously
for primaquine (11).
In vivo therapy studies with all three compounds were
performed at doses of 2.0 mg/kg, because this was the dose
of primaquine that was effective in combination with clinda-
mycin for therapy in rats (11). In all studies scores for both
Giemsa- and silver-stained slides are shown because dif-
ferent features are emphasized. Giemsa stain shows the
higher scores for trophozoites, and silver stain may detect
rare cysts.
In the first therapy study, which was done at IU, we used
TABLE 2. Treatment at IU of P. carinii pneumonia with 8-aminoquinolines from WRAIR alone and with clindamycin
Dose Giemsa stain No. infected/ Silver stain No. infected/
Drug(mg/kgtday) infscore' total no. infectivity score' total no.
WR6026 2 0.2 ± 0.1b 5/10 0.4 ± 0.2 6/10
WR6026 + clindamycin 2/225 0.3 ± 0.2b 4/10 0.9 ± 0.3 9/10
WR238605 4 0.06 ± 0.1b 3/10 0 0/10
WR238605 + clindamycin 4/225 0.1 ± 0.1b 4/10 0.1 ± 0.1 4/10
WR242511 2 0.03 ± 0.1b 1/10 0 0/10
WR242511 + clindamycin 2/225 0.1 ± 0.1b 2/10 0.1 ± 0.1 4/10
Primaquine + clindamycin 2/225 0.3 ± 0.2b 3/10 0.5 ± 0.1 7/10
Untreated 3.9 ± 0.2 10/10 3.4 ± 0.2 10/10
Trimethoprim-sulfamethoxazole 50/250 0.03 ± 0.lb 1/10 0.3 ± 0.2 3/10
a Results are expressed as means ± standard errors. The scores are described in the text.
b p < 0.001 compared with untreated controls.
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TABLE 3. Extent of disease by histologic score at UNC
No. of animals with the following scores:
Compound or drug Dose (mg/kg/day) Mean score
0.5 1 2 3 4
Saline 3.0 (3.3)a 0 (0) 0 (0) 1 (0) 8 (7) 1 (3)
Clindamycin 225 2.8 (2.5)b 0 (0) 0 (1) 5 (4) 2 (4) 3 (1)
WR238605 4.0 0.9 (0.8)bc 4 (5) 5 (5) 1 (0) 0 (0) 0 (0)
WR238605 + clindamycin 4.0/225 0.5 (0.9)b,d 7 (2) 0 (5) 0 (0) 0 (0) 0 (0)
WR242511 2.0 0.6 (0.6)b.d 9 (8) 1 (2) 0 (0) 0 (0) 0 (0)
WR242511 + clindamycin 2.0/225 0.8 (0.9)bc 5 (6) 2 (1) 1 (0) 0 (1) 0 (0)
WR6026 2.0 0.7 (0.8)bd 6 (5) 4 (5) 0 (0) 0 (0) 0 (0)
WR6026 + clindamycin 2.0/225 1.0 (0.9)bd 3 (2) 6 (8) 1 (0) 0 (0) 0 (0)
a Numbers in parentheses indicate the results of the second scorer.
b p = 0.0001 compared with saline controls.
c P > 0.0005 compared with controls treated with clindamycin only.
d p = 0.0001 compared with controls treated with clindamycin only.
immunosuppression with dexamethasone and drug treat- nosuppression was with dexamethasone. The compounds
ment by gavage once per day. All three drugs were effective were active at 0.25 mg/kg/day for WR242511 and 0.5 mg/kg/
(Table 1). Animals that received clindamycin at 225 mg/kg in day for WR6026 and WR238605.
addition to the 8-aminoquinolines- once per day by gavage The three drugs were also tested at IU for their effective-
had scores similar to those of the groups that received ness in prophylaxis (Table 5). Drugs were given in the
8-aminoquinolines alone (data not shown). drinking water, and immunosuppression was with dexameth-
A second qudy was performed at both IU and UNC by asone. All three compounds were effective at 0.57 mg/kg/day.
using their respective models. The data from the study In a separate study, primaquine also was tested in a
performed at IU are shown in Table 2. Animals were immu- prophylaxis model of rats immunosuppressed with cortisone
nosuppressed with cortisone acetate, and drug doses were acetate given subcutaneously with and without glindamycin
given in drinking water. Again, all three drugs were effective. at 225 mg/kg/day in drinking water (Table 6). Primaquine
In the comparaule study at UNC, the same lots of drugs showed minimal effectiveness when used alone at a dose of
provided by WRAIR to IU were used. Table 3 shows the 0.57 mg/kg/day but was quite effective when used at this
results of the study done at UNC by using their scoring dose in combination with clindamycin.
system. The findings are comparable to those obtained at IU.
A third therapy study was performed at IU to establish the DISCUSSION
lowest effective doses of the compounds (Table 4). The
protocol was similar to that used in the second study (Table Results of the studies done at IU and UNC establish the
2); drug doses were given in the drinking water, and immu- efficacy of the 8-aminoquinolines WR238605, WR242511,
TABLE 4. Establishment at IU of lowest effective dose for therapy of P. carinii pneumonia with 8-aminoquinolines from WRAIR
Dose Giemsa stain No. infected/ Silver stain No. infected/
(mg/kg/day) infectivity scorea total no." infectivity scorea total no."
WR6026
2.0 0.3 ± 0.1 3/5 0.4 ± 0.2 3/5
1.0 1.1 ± 0.2 5/8 0.9 ± 0.4 5/8
0.5 1.8 ± 0.6 7/7 2.1 ± 0.4 7/
0.25 4.7 ± 0.2 7/7 3.9 + 0.1 7/
WR238605
4.0 0.03 ± 0.1 1/7 0.3 ± 0.2 3/7
2.0 0.9 + 0.4 4/6 1.0 ± 0.4 5/6
1.0 2.3 ± 0.9 5/5 2.4 ± 0.6 5/5
0.5 2.6 ± 0.2 3/3 2.7 ± 0.1 3/3
WR242511
2.0 0.16 ± 0.2 1/2 0.5 ± 0.2 2/2
1.0 0.5 ± 0.2 3/6 0.8 ± 0.3 4/6
0.5 2.4 ± 0.8 4/5 2.2 ± 0.6 4/5
0.25 1.8 ± 0.6 7/7 1.8 ± 0.5 7/7
0.1 4.0 _ 0.3 8/8 3.6 ± 0.2 8/8
Trimethoprim-sulfamethoxazole 50/250 0.9 0.6 3/5 0.4 0.1 4/5
Untreated 4.2 ± 0.2 8/8 3.6 ± 0.2 8/8
a Results are expressed as means ± standard errors. The scores are described in the text.
b Total is the number of rats for which evaluable slides were obtained; animals that died during the study were not always evaluable.
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TABLE 5. Prophylaxis at IU of rats with P. carinii pneumonia with 8-aminoquinolines from WRAIR
Dose Giemsa stain No. infected/ Silver stain No. infected/
Drug (mg/kg/day) infectivity score" total no. infectivity score' total no.
WR6026 0.57 0.09 ± 0.1b 3/10 0.4 ± 0.1 6/10
WR238605 0.57 0.4 ± 0.2b 4/10 0.4 ± 0.2 4/10
WR242511 0.57 ob 0/7c 0.1 ± 0.1 2/7c
Trimethoprim-sulfamethoxazole 50/250 0.07 ± 0.1b 2/10 0.1 ± 0.1 2/10
Untreated 4.0 ± 0.3 8/8C 3.3 ± 0.2 8/8
a Results are expressed as means + standard errors. The scores are described in the text.
b p < 0.001 compared with untreated controls.
C Three rats in the group treated with WR242511 and two untreated rats died soon after the start of the experiment; neither drug therapy nor P. carinii infection
appeared to be contributing factors.
and WR6026 for the treatment of Pneumocystis pneumonia.
These three compounds were effective for treatment at doses
of 1 mg/kg/day or less (1.7 to 2.4 ,umol/kg/day), whereas
primaquine was somewhat effective at 2 mg/kg/day (4.4
,umol/kg/day) and showed better activity at this dose when
combined with clindamycin at a dose of 225 mg/kg/day.
Results of the second and third of the three therapy studies
were comparable (Tables 2 and 4). In both of these studies,
drugs were given in drinking water. In the first therapy study
(Table 1), the drugs were less effective, although their
effectiveness was clearly different from that of the control,
possibly because the drugs were given by gavage in a single
daily dose. In earlier experiments (unpublished data) we
observed that clindamycin is effective in combination with
primaquine when given continuously in water but is ineffec-
tive when given once daily by gavage.
The models for animal studies at IU and UNC differed in
several significant ways. IU used smaller female rats, while
UNC used older, heavier male rats. No study has specifi-
cally addressed the susceptibility of rats to either P. carinii
infection or immunosuppression related to the age and sex of
the animals, although it is known that sex hormones can
affect the immune response (9). At IU, animals received a
regular diet, while at UNC animals received a low-protein
diet. Diarrhea was noted in the clindamycin-treated rats at
UNC (Table 7), while none was detected at IU. The diarrhea
noted at UNC might have been related to the low-protein
diet, the different intestinal flora of the rats, or both. In
clinical trials with the combination of clindamycin and
primaquine, diarrhea has not been a significant problem.
Finally, although there were many differences in the
animal models, including sex, body size, diet, source of P.
carinii, and evaluation systems, both models yielded com-
parable evaluations of these drugs for therapy.
Compounds WR6026, WR238605, and WR242511 also
were effective for prophylaxis against Pneumocystis pneu-
monia when given continuously at daily doses of 0.57 mg/kg
(1.4, 0.98, and 1 ,umol/kg, respectively) (Table 5). At that
same dose, primaquine alone (1.25 ,umol/kg) showed only a
weak effect but was effective in combination with clindamy-
cin (Table 6).
For prophylaxis the 8-aminoquinolines were used at doses
of 0.57 mg/kg, because a previous study (11) showed that this
dose of primaquine combined with clindamycin at 225 mg/kg
effectively prevented the development of P. carinii pneumo-
nia. In the clindamycin-primaquine prophylaxis study (Table
6), primaquine alone at 0.57 mg/kg reduced the infectivity
score by about one unit (roughly equivalent to a 90%
decrease in the numbers of organisms). At that same dose,
the WRAIR 8-aminoquinolines were more effective than
primaquine and possibly could be used in much lower doses
or in less frequent dosing regimens. Combination with clin-
damycin might provide even better prophylactic regimens.
In future studies, we hope to establish the lowest effective
doses for prophylaxis and to suggest optimal dosing regi-
mens.
Although synergy between clindamycin and primaquine
has been demonstrated in both therapy and prophylaxis
models of Pneumocystis pneumonia, no such synergy has
yet been demonstrated between the newer WRAIR 8-ami-
noquinolines and clindamycin, because the animal therapy
studies which used 8-aminoquinolines in combination with
clindamycin showed that the 8-aminoquinolines alone had
excellent activities at the doses used. The dose range study
of the three 8-aminoquinolines established that the lowest
active doses were 0.25 to 0.5 mg/kg for WR242511 and 0.5 to
1.0 mg/kg for WR238605 and WR6026. With these dose
ranges established, clindamycin combination studies can be
performed to assess synergy and the possibility of using even
lower doses of these 8-aminoquinolines when they are given
in combination with clindamycin.
Although mechanisms of action have not been established
for lincosamines such as clindamycin or for 8-aminoquino-
lines against P. carinii, both classes of drugs have been used
for 15 years or more for the treatment of bacterial infections
and Plasmodium vivax malaria. Methemoglobinemia is a
TABLE 6. Prophylaxis at IU of rats with P. carinii pneumonia with primaquine or primaquine plus clindamycin
Drug' Dose Giemsa stain No. infected/ Silver stain No. infected/
(mg/kg/day) infectivity scoreb total no. infectivity score total no.
Clindamycin + 225/0.57 1.4 ± 0.4c 8/11 1.8 ± 0.3 11/11
primaquine
Primaquine 0.57 3.3 ± 0.3 7/7 3.2 ± 0.2 7/7
Untreated 4.4 ± 0.3 5/5 3.9 ± 0.1 5/7
a Drugs were administered in drinking water; immunosuppression was with cortisone acetate administered at 250 mg/kg subcutaneously twice weekly.
b Results are expressed as means ± standard errors. The scores are described in the text.
C P < 0.001 compared with untreated controls.
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TABLE 7. UNC toxicity score
Group (dose [mg/kg]) Toxicity Effectscore'
Untreated None, untreated controls
Clindamycin (225) 1+ Severe diarrhea in wk 8
of immunosuppression
WR238605 (4) 0 None
WR238605 (4) + 2+ Three rats died, severe
clindamycin (225) diarrhea in wk 8 of
immunosuppression
WR242511 (2) 0 None
WR242511 (2) + 2+ Two rats died, severe
clindamycin (225) diarrhea in wk 8 of
immunosuppression
WR6026 (2) 0 None
WR6026 (2) + 1+ Severe diarrhea in wk 8
clindamycin (225) of immunosuppression
a The toxicities of the test compounds were evaluated and scored as
follows: 0, no observed local, clinical, or histologic toxicity; 1+, all animals
survived the test dose without severe distress and no histopathology was
noted; 2+, all animals survived the test dose but were observed to have
clinical side effects, some histopathology, or both.
frequent consequence of primaquine therapy, and hemolysis
may occur in patients with glucose 6-phosphate dehydroge-
nase deficiency. The WRAIR compounds have less of a
potential than primaquine to cause methemoglobinemia be-
cause they can be used at much lower doses than primaquine
can.
The rat model has predicted the usefulness of a number of
drugs for treatment and prophylaxis of Pneumocystis pneu-
monia (4, 7, 10). The successful treatment and prophylaxis
studies reported here suggest that clinical evaluations of
these interesting orally administered compounds should be
considered.
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